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A B S T R A C T
Purpose: The incidence of sudden death appears to be 20 times higher in patients with epilepsy
compared with the general population. Epilepsy-related death, particularly sudden unexpected death in
epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reﬂect the mistaken
belief that epilepsy is a benign condition. The risk of death associated with epilepsy appeared rarely to
have been discussed with patients or their families. It appears the decision to discuss SUDEP and also to
peg SUDEP risk is arbitrary and clinical. Unfortunately there is no structured evidenced mechanism at
present to represent person centered risk of SUDEP and there is currently no easy manner or template to
have this discussion with the family and the patient.
Methods: We conducted a detailed literature review in Medline, Embase and Psychinfo databases to
extract the common risk factors as evidenced from literature till date. Research into risk factors has
identiﬁed a number of risk factors for SUDEP, some of which are potentially modiﬁable.
Results: Based on the literature review, we believe that the ascertained risk factors could be employed in
clinical practice as a checklist to reduce an individual patient’s risk of SUDEP. The SUDEP safety checklist
may be of practical use in reducing risks in some individuals and is deﬁnitely of use in helping
communication.
Conclusions: An evidence based checklist identifying the major risk factors can help both clinicians and
patients to focus on minimizing certain risk factors and promote safety by focusing on the modiﬁable
factors and guide treatment. It can be a tool to open a person centered discussion with patients and to
outline how individual behaviors could impact on risk.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsy is a major global health problem; it is the most
common chronic disabling condition of the nervous system
affecting an estimated 50 million people worldwide1 and around
400,000 people in the UK.2
Epidemiological studies consistently report a standardized
mortality rate (SMR) of 2–4 for epilepsy. In newly diagnosed
epilepsy, death is largely attributable to the underlying disease (for
example, vascular disease, and tumor). In chronic epilepsy,
however, the main cause of excess mortality is death during a
seizure: sudden unexpected death in epilepsy (SUDEP).* Corresponding author. Tel.: +44 1872221553.
E-mail address: Rohit.shankar@cft.cornwall.nhs.uk (R. Shankar).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.07.014SUDEP is estimated to account for 500 deaths a year in the UK.5
The incidence of sudden death appears to be 20 times higher in
patients with epilepsy compared with the general population, and
SUDEP is the most important directly epilepsy-related cause of
death. However, the risk varies markedly between different epilepsy
populations. SUDEP is uncommon in patients with new onset
epilepsy and in patients in remission where the incidence has been
estimated to 0.1–0.35 cases in 1000 person years in population-
based cohorts of epilepsy patients. It is considerably higher in
patients with chronic epilepsy, 1–2 per 1000 person years, and
highest among those with severe, refractory seizures, 3–9 per 1000.
SUDEP may occur at all ages, with highest rates between 20 and 40
years. In most cases SUDEP appears to be seizure-related.6
Epilepsy-related death, particularly SUDEP, is still under-
estimated by healthcare professionals and this may reﬂect the
mistaken belief that epilepsy is a benign condition. The risk ofvier Ltd. All rights reserved.
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discussed with patients or their families. There was little
documented evidence of contact with bereaved relatives after
death;2 leading to signiﬁcant emotional trauma when SUDEP
happens leaving families and clinicians searching for answers. It is
important for people with epilepsy and their families to be aware
of the risks associated with epilepsy. A small number of people
have a risk of sudden death due to their epilepsy. Most people who
know somebody who has died due to epilepsy say they wished
they had known more about the risks before the person died.
The NICE and SIGN guidelines both advocate discussion of SUDEP
with the patient at the earliest.5,25A fatal accidental enquiry into two
epilepsy deaths concluded in 2011 that the risk of SUDEP should be
advised to patients and carers unless in the case of a particular
patient there is a risk of serious harm. It also advised that the
information and advice about SUDEP should be provided directly by
the consultant in charge of the patient’s case or, where appropriate,
by an epilepsy specialist nurse.5 On the other hand clinicians
working in epilepsy feel that bringing the issue of death into
preliminarily consultations could have a stigmatizing effect while
also having an impact on the therapeutic relationship. A survey
among UK neurologists showed that only 4.7% of them discussed
SUDEP with all patients and 25.6% with the majority. The rest
discussed the risk of SUDEP with very few or no patients.16 A recent
retrospective case note series shows only 4% recorded a discussion of
SUDEP.17 It appears the decision to discuss SUDEP and also to peg
SUDEP risk is arbitrary and clinical. Unfortunately there is no
structured evidenced mechanism at present to represent person
centered risk of SUDEP and there is currently no easy manner or
template to have this discussion with the family and the patient.
An evidence based checklist identifying the major risk factors
can help both clinicians and patients to focus on minimizing
certain risk factors and promote safety by focusing on the
modiﬁable factors and guide treatment. It can be a tool to open
a person centered discussion with patients and to outline how
individual risk factors could impact on overall risk.
For patients it opens up discussion around a sensitive, complex
and difﬁcult topic. It gives better understanding of what risk
factors lay in the locus control of the patient and which are not. It
helps patients make informed choices. A recorded person centered
discussion would help reduce corporate risk and potential
complaints too.
We wished to review the available literature to inform the
development of a safety checklist for sudden death in epilepsy
(SUDEP). The SUDEP safety checklist may be of practical use in
reducing risks in some individuals.
2. Methodology
We conducted a search in Medline, Psychinfo and Embase
databases with the following keywords: Risk AND factors
combined with SUDEP, sudden AND death AND in AND epilepsy,
sudden death in epilepsy.
52 studies were initially identiﬁed using these criteria. These
considered many putative risk factors for SUDEP from progressive
deterioration in heart rate variability to thalamic nuclear
abnormalities.7–15 Many studies were seeking to elucidate
potential mechanisms for SUDEP using a small number of cases
from a specialist center. Relatively few studies involved a
population based sample. We decided to restrict our review to
population based studies where a control group was employed.
3. Results
Nilsson et al. conducted a retrospective nested case control
study in Stockholm with the objective of investigating theassociation between several clinical variables and SUDEP.18 The
6880 population studied was limited to those who had been
admitted to hospital with a diagnosis of epilepsy in the study
period. The authors estimated that 60% of the adult epilepsy
population of Stockholm was included in the cohort. Case
ascertainment was based on a national cause of death register
and the authors’ criteria for a SUDEP case. Each case was compared
with 3 randomly selected controls. The authors excluded four
cases from their analysis who had received AED treatment for less
then one year.
The authors found the largest increase in relative risk for SUDEP
associated with seizure frequency greater then 2 per year with
escalating relative risk for higher frequencies (RR 10.16 for more
than 50 seizures per year). The authors did not distinguish between
seizure types. The risk of SUDEP increased with increasing number
of antiepileptic drugs taken concomitantly – 989 for three
antiepileptic drugs compared with monotherapy. When the
authors statistically controlled for seizure frequency this associa-
tion persisted. Among men the RR for SUDEP was 17.64 in those
whose epilepsy had its onset prior to age 15 compared with onset
after age 45 with a weaker trend in the same direction for females.
Frequent changes of AED dose (3–5 dose changes) in the last year
compared with no changes were associated with an RR of 6.08. A
threefold increase in RR was seen in those taking anxiolytic
medications, especially men.
In relation to seizure frequency the authors had a category of
unknown. This group represented patients who were not seizure
free, but in whom medical notes were not sufﬁciently detailed to
allow further calculation. This group had the strongest association
with SUDEP of all seizure frequency groups (RR = 15.04). The
authors did not ﬁnd an increase in RR for SUDEP in the following
groups: patients with heart disease, cerebrovascular disease or
alcoholism. They did ﬁnd an increase in RR in patients with a
history of injuries (non CNS).
Walczak et al. conducted a prospective cohort study in 3
centers in the Midwest of America of patients presenting to
epilepsy centers.19 In all they prospectively followed up 4578
patients for a total of 16,463 patient-years. The majority of
patients underwent extensive evaluation including identiﬁcation
of epileptiform discharges on interictal EEG or electrographic
seizures (90% of cohort), AED levels and seizure type. 111 deaths in
the study period were reviewed against SUDEP criteria by a
committee of investigators including a SUDEP expert. There was a
cross checking mechanism permitting identiﬁcation of unreport-
ed deaths.
Deaths were classiﬁed as deﬁnite or probable SUDEP, possible
SUDEP and non SUDEP. The following risk factors were studied:
age at enrolment, gender, number of seizures of any sort in 12
months prior to last visit, number of tonic–clonic seizures in the
12 months preceding the last visit and duration of epilepsy. The
authors also examined the effect of mental retardation, epilepto-
genic structural lesions; number of AED used at last visit,
psychotropic drug use and whether AEDs were at therapeutic
levels. Ten risk factors were examined in total by the group where
there were 20 cases of SUDEP (deﬁnite or probable).
The authors found a progressive increase in the risk for SUDEP
with increased seizure frequency (any seizure type) which was
signiﬁcant only when there were more than 50 seizures per month
(OR = 11.5). When Generalized Tonic Clonic Seizure (GTCS) were
examined speciﬁcally as few as 1–3 per year were associated with
an increased risk of SUDEP (OR = 2.4). Greater then 3 GTCS per year
were associated with an OR of 8.1.
They also found an association between long duration of
epilepsy (>30 years) and SUDEP (OR = 13.9). Likewise mental
retardation (IQ < 70, as measured by WAIS) was associated with
SUDEP with an OR of 5. The number of AEDs used remained a risk
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GTCS (OR = 3).
The main strengths of this study were that it was a
population based prospective cohort study in which epilepsy
diagnoses were secure. In the majority of patients a range of
clinical information was available e.g. AED levels. Weaknesses
included the number of associations tested for when there were
only 20 cases, some cases did not undergo post mortem
examination and that the population was one attending epilepsy
centers so that the severity of epilepsy may have been higher
than in a purely geographically identiﬁed population.
Langan reported a retrospective case control study of SUDEP
based on deaths identiﬁed through the coroner, neurologists or
bereaved families.20 Controls (4 per case) were taken from the MRC
General Practice Research framework. 154 cases in which an
autopsy was performed were identiﬁed. Odds ratios for fourteen
putative risk factors were determined by backward stepwise
conditional logistic regression analysis. Variables with more than
35% of the data missing were excluded from the analysis. The
analysis controlled for frequency of convulsive seizures so that the
effect of other variables could be assessed independently of their
relationship to seizure frequency.
A history of generalized tonic–clonic seizures (OR = 13.8) and a
high frequency of them in the recent past (OR > 10 for more than
10 GTCS in previous 3 months) were associated with a signiﬁcant
increase in the risk of SUDEP. The authors’ ﬁndings suggested an
association with Carbamazepine and SUDEP but the OR of 2 had a
95% conﬁdence interval including 1. The authors did not ﬁnd
current polytherapy an independent risk factor for SUDEP, but did
ﬁnd that greater numbers of AEDs ever taken were associated with
higher risk as was an unclear treatment history and no treatment.
The presence of supervision at night was found to be protective
against SUDEP (OR = 0.4) when a supervising individual shared the
same bedroom or when special precautions such as a listening
device were employed (OR = 0.1).
Hesdorffer et al. pooled the data from four published case
control studies which had live controls to increase power to
determine risk factors.24 They aggregated data from the Nilsson
et al. (1999), Walczak et al. (2001), Langan et al. (2005) and Hitiris
et al. (2007). We have described three of the four (excluding Hitiris
et al., 2007) in detail above. The pooled data had a total of 289 cases
and 958 controls. Chief risk factors which were prominent
included increase in frequency of generalized seizures, duration
of epilepsy, young age of onset, gender, symptomatic etiology and
Lamotrigine therapy. The pooled data results were largely
consistent with the ﬁndings of the results of the individual studies
though the analysis revealed certain signiﬁcant variances. In
particular they identiﬁed hitherto unassociated factors such as
Lamotrigine therapy, male gender and symptomatic etiology. As
with any combined analysis this work is vulnerable to the
heterogeneous nature of the study population and methodology
employed in the individual studies.
Hughes et al. attempted to provide up-to-date quantitative
data from published reports on sudden unexpected death in
epilepsy (SUDEP) appearing on Medline and, especially, to
provide a means to predict the probability of SUDEP in a given
patient.12 The mean incidence of SUDEP was 1.8/1000, similar to
the median of 1.5. The mean standardized mortality ratio was
6.8, and the mean percentage of SUDEP cases among deaths from
epilepsy was 16.6. Seventeen risk factors were identiﬁed, each
given a value according to the number of studies in the literature
that speciﬁed that condition as a signiﬁcant risk. The addition of
these 17 values then indicated the risk for a given patient. The
author calculated these for a group of 91 patients who died of
SUDEP and also for 91 live control patients with epilepsy. Many
of the values for the SUDEP cases were signiﬁcantly different.The sensitivity of the risk factor analysis was 71.3%, the
speciﬁcity 81.8%, and the positive predictive value 84.6%. A
discussion includes the question of whether the death in SUDEP
is primarily due to cardiac or pulmonary mechanisms and a
suggestion that it may be either or both in a given patient. The
most important risk factor in this study was non-compliance
with antiepileptic medication, and the main message of this
study to caregivers is that therapeutic drug levels are crucial to
avoid SUDEP.
Monte et al. aimed to review systematically risk factors for
SUDEP and also to determine their relevance for SUDEP by
calculating relative risk factor ratios.13 The authors performed a
literature-search on ‘‘SUDEP’’. Studies with unknown number of
SUDEP cases or those with less than ﬁve SUDEP cases and reviews
were excluded from further analysis. The value of each paper was
assessed, based on the quality of the study and the reliability of the
diagnosis of SUDEP. This value ranged from 1 (low quality) to 10
(high quality). Papers with a value below 7 were eliminated for
further analysis. For each analyzed factor, a risk factor ratio was
determined, with a higher ratio for a stronger risk factor.
With this methodology the authors identiﬁed a number of
strong risk factors for SUDEP: young age, early onset of seizures,
the presence of generalized tonic clonic seizures, male sex and
being in bed. Weak risk factors for SUDEP included prone position,
one or more subtherapeutic blood levels, being in the bedroom, a
structural brain lesion and sleeping. The authors used a transpar-
ent methodology for identifying risk factors and rating the quality
of studies. They acknowledge that their risk factor value method
has not been validated previously. Excluding studies with less than
5 SUDEP cases may have failed to identify risk factors of small
effect.
Tellez-Zenteno et al. did a systematic review to provide an
evidence-based analysis of the risk factors and incidence of SUDEP,
and to assess methodological aspects and sources of variation in
studies dealing with SUDEP.21
They searched Medline, Index Medicus, and the Cochrane
library and included case-control or cohort studies focusing on
SUDEP in children or adults, published in the English language.
They found 404 citations, 83 potentially eligible articles were
reviewed in full text and 36 studies fulﬁlled eligibility criteria (29
cohort and 8 case-control studies). They drew a distinction
between the ﬁndings in studies using non-SUDEP deaths as
controls and studies using living patients with epilepsy. For the
ﬁrst category the most consistent risk factors were a seizure
preceding death, and subtherapeutic antiepileptic drug levels. In
studies that used persons living with epilepsy as controls the main
risk factors for SUDEP were youth, high seizure frequency, high
number of antiepileptic drugs and long duration of epilepsy. They
found an annual incidence of SUDEP ranging from 0 to 10/1000. It
was highest in studies of candidates for epilepsy surgery and
epilepsy referral centers (2.2 to 10/1000), intermediate in studies
including patients with intellectual disability (3.4 to 3.6/1000), and
lowest in children (0 to 0.2/1000). The incidence was similar in
autopsy series (0.35 to 2.5/1000–) and in studies of epilepsy
patients in the general population (0 to 1.35/1000). The median
proportion of SUDEP in relation to overall mortality in epilepsy was
40 and 4% in high- and low-risk groups, respectively.
The authors concluded that although studies on SUDEP are
heterogeneous in methodology, consistent patterns in incidence
and risk factors emerge. Low- and high-risk patient groups
are identiﬁed, which determine the relative contribution of SUDEP
to overall mortality in epilepsy. In addition to patient population,
risk factors for SUDEP depend on the type of controls used for
comparison (dead versus live patients with epilepsy). Risk factors
found in different studies are not necessarily contradictory, but are
often complementary.
Table 1
Statistics of salient ﬁndings of relevant studies.
Risk factor Range Cases n Controls n OR (95% CI) Authors
Early onset of epilepsy in men >45 yrs 4 25 1.00 (reference) 18
<15 yrs 11 10 17.64 (2.65–117.60)
Full scale IQ (WAIS) >79 5 36 1.00 (reference) 19
<70 7 10 5.0 (1.3–19.3)
Presence of supervision at night None 109 169 1.00 (reference) 20
Same room 34 156 0.4 (0.2–0.8)
Number of concomitant AEDs 1 22 115 1.00 (reference) 18
3 12 7 9.89 (3.20–30.60)
Time since last anticonvulsant prescription <90 days 8250 10847 1.00 (reference) 22
365 days 908 5019 0.24 (0.22–0.26)
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epilepsy mortality rates in a UK general practice database.22 We
included their study in our review because of the large population
followed up and the ﬁnding of 3 risk factors for general mortality in
epilepsy coinciding with risk factors identiﬁed in SUDEP speciﬁc
studies. A nested case control study design was used and 434 GP
practices were included involving 3.3 million patients in 2007. The
study time frame was 1993–2006 and patients with epilepsy dying
of any cause were included in the analysis. Over the period the
prevalence of epilepsy in the study population increased from 9/
1000 in 1993 to 12/1000 in 2007. Epilepsy deaths also increased in
this period. The authors found mortality to be associated with:
1. Recorded alcohol problems, OR = 2.96.
2. Collection of AED 3–6 months ago, OR = 1.83.
3. Having an injury in the previous year, OR = 1.41.
4. Treatment for depression, OR = 1.39.
By contrast the authors found being recorded seizure free in
previous 12 months (2004 data onwards) was associated with
lower mortality, OR = 0.78. It is important to recognize that this
study looked at epilepsy mortality in general and not SUDEP in
particular.
The statistics for some of the major studies in this paper are
shown in Table 1. The available data seems to suggest that the
following are well-recognized risk factors for SUDEP:13,15
 Having uncontrolled generalized tonic–clonic seizures.
 Not taking anti-epileptic drugs (AEDs) as prescribed.
 Having tonic clonic seizures that are not controlled by AEDs.
 Having sudden and frequent changes to AEDs.
 Being a young adult (in particular male).
 Having sleep seizures.
 Having seizures when alone.
 Drinking large amounts of alcohol.
4. Discussion
Our literature review identiﬁes certain factors which appear to
have a higher risk potential contributing to SUDEP than others. Wecould not ﬁnd any papers where this research has been transferred
into a communication tool or a risk safety list to engage patients in
as we propose to do.
While it is not yet known how to prevent SUDEP, one needs to
see if we can minimize the risk factors which might lead to SUDEP.
An evidence based risk checklist (Appendix 1) can help both
clinicians and patients to focus on minimizing certain risk factors
and promote safety.
For clinicians it would be an objective and quick way of looking
at risk factors of SUDEP, especially the modiﬁable factors. It could
help guide treatment by being a potential reﬂector of change in
status in risk and help justify their actions. It would also help as a
tool which can be used as a medium to open discussion with
patients who have risk factors and to outline how individual
behaviors could impact on risk (for example – lack of compliance
seen in association with types of seizures happening could be
highlighted on the checklist and shown during discussion which
might then bring about insight in the patient).
For patients it opens up discussion around a sensitive, complex
and difﬁcult topic. It gives better understanding of what risk
factors lay in the locus control of the patient and which are not. It
helps patients make informed life style choices.
From a corporate perspective23 there is clarity in recording of
discussion in a structured evidence manner and evidence of
change. No attempt has been made to rank these risk factors. The
tool can be used in daily clinical practice as it is simple and quick to
use. A copy of the checklist could be placed in the patient’s medical
notes as evidence. Where an overall SUDEP risk rating is increasing
in relation to the individual the clinical team can intervene to
mitigate the risks or use it to evidence the difﬁculty in changing the
risks inspite of attempts to reduce risk.
Therefore it would help quantify certain risk issues linked to
SUDEP and to raise awareness of them in partnership with the
patient and carer with a view to promoting safety in a structured
manner.
Our thanks to SUDEP Action for the educational Grant and
support we received to develop the checklist.
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Appendix A
SUDEP Sa fety Checkli st  Version 1.0 dated 11
th
Se pte mber 201 2
SUDEP safety checkli st
Static f actors evidence present  /absent
Male  sex Descripti ve studies commonly fou nd,  but  not  replicated 
in controlled studies.
Duration of epilepsy  (15-
30years)
Suggeste d by several  studies, but  not  afte r mu ltiple 
logistical  regres sion analysis for  seizure frequency 
Unclear  treatment history Reporte d finding
Primary generalised epilepsy (in 
men only)
Few studies small numbers
Intellectual disability Limited evidence
Modifiable factors
Severity of sei zures Not  quantifie d in studies
Number of AEDs Has been reporte d (not  universal ly)as an independent 
risk factor ( afte r corr ecti on for  seizure frequency)
Compli ance issues Implied by finding of varia ble  AED hair  strand levels in 
SUDEP group of controls. Not  collected AED last 3 
months (Ridsdale et  al  20 11).
Frequent AED prescribing 
changes
Implied by finding of  varia ble  AED hai r strand levels in 
SUDEP vs. group cf controls
Sub therapeutic AED le vels Not  fou nd to be a factor  in most studies
Lamotrigine Hesdorff er et  al  study on combining the data of the 4 
case control studies in SUD EP
Carb amazepine Small nu mber of studies have implicated as independent 
risk factor
Reporte d alcohol  problem Ridsdale et  al  2011:  ass ociated with overall increase in 
mortali ty 
Treatment for  depres sion Ridsdale et  al  2011:  ass ociated with overall increase in 
mortali ty
Anxiolytic medication Nilsson et  al  1999  
Mode rate risk-static f actors
Younger age Comm only found in descriptive studies, but  biases exist. 
In controlled studies 70-80%  les s than 45  yrs old.
Moderate risk-modifiable factors
No surveillance at  nigh t Several  studies independent  risk factor
Prone position Several  studies independent  risk factor
Failed as sessment for  epilepsy 
surgery
Higher SUDEP inci dence if no surgery cf successful 
VNS
Establ ished risk-static f actor
Early onset  of epilepsy Several  controlled studies suggest increased risk. 8 fold 
increased risk age 0-15 reported in one controlled study 
(cf >45yrs)
Establ ished risk-modifiable factor
High seizure frequency esp. 
convulsive sei zures
Several  descripti ve and la rge case control studies,  but  not 
all fou nd increased risk
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